Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, is pleased to announce that Algernon's CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company's interim data report for the Company's Phase 2b3 clinical study of Ifenprodil for COVID-19 on an upcoming BioPub webcast.

The BioPub webcast will be held Thursday December 17, 2020 hosted by Dr. KSS at noon EDT. The Company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.

BioPub has been analyzing small-cap special situation biotech investments for seven years to readers in over 40 countries.

BioPub.co
Discussing Ifenprodil Interim Data With Algernon Pharmaceuticals
When: Dec 17, 2020 12:00 PM EDT

Please click the link below to join the webinar:
https://us02web.zoom.us/j/83294585006

Or iPhone one-tap :
US: +16465588656,,83294585006# or +16699009128,,83294585006#

Telephone:
US: +1 646 558 8656 or +1 669 900 9128 or +1 253 215 8782 or +1 301 715 8592 or +1 312 626 6799 or +1 346 248 7799

Webinar ID: 832 9458 5006

International numbers available: https://us02web.zoom.us/u/k1kXNAOXt

About   BioPub

BioPub.co is a biotech investment discussion website. Our goal is to be the secret weapon and unfair advantage of every subscriber. What you will find is an education including interviews others don't get and presence at meetings others don't bother to attend. We promote what we consider best in class companies and follow them closely to ensure that management is executing their business plan faithfully and that development trials proceed as expected. We leverage the knowledge brought to the table by our professional members to see if the products being brought to market make sense financially in a world whose rules are changing daily.

About Algernon Pharmaceuticals Inc.

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com  
  investors@algernonpharmaceuticals.com  
  www.algernonpharmaceuticals.com .

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Young female researcher working in a lab.

Radiopharmaceuticals Take Investors to the Forefront of Precision Oncology

Radiopharmaceuticals are emerging as one of the most promising innovations in modern medicine, particularly in precision oncology, and if recent billion-dollar investment deals are any indication, the potential for growth can be significant. Investors eyeing exposure to this emerging technology would benefit from a deeper understanding of the technology, its strategic applications and investment opportunities.

A groundbreaking technology in the field of oncology, radiopharmaceuticals combine radioactive substances with targeted molecules to revolutionise cancer detection and treatment. These innovative compounds are gaining significant attention due to their ability to deliver precise and targeted cancer therapies, minimising damage to healthy tissues while maximising therapeutic efficacy.

At their core, radiopharmaceuticals leverage the unique properties of radioactive isotopes, pairing them with molecules that have a high affinity for cancer cells. This combination allows for both diagnostic imaging and therapeutic applications, offering a level of precision previously unattainable in traditional cancer treatments.

Keep reading...Show less
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology .

About the Study

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

Howard Chang , M.D., Ph.D.,   Joins as Senior Vice President of Research and Chief Scientific Officer

Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Top 5 Life Science ETFs in 2024

Top 5 Life Science ETFs in 2024

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.

While ETFs provide diversification by their nature, fund managers often narrow down their offerings to follow a specific aspect of the market — for example, biotech or pharma. They also typically adjust the weight of ETF holdings to match movements in the life science industry in an effort to give investors the best possible returns.

There are many choices when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top life science ETFs by year-on-year performance.

Keep reading...Show less
Radiopharm Theranostics

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to include participants with Programmed Death-Ligand 1 (PD-L1) positive Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Melanoma, Head and Neck Cancer (HNSCC), and Endometrial Cancer, as part of its ongoing Phase 1 clinical trial of 177Lu-labelled RAD204 for the treatment of PD-L1 expressing cancers.
Keep reading...Show less

Latest Press Releases

Related News

×